ArticleAntonie van Leeuwenhoek2026
Age-related susceptibility to high-dose fecal microbial administration in young mice.
Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The safety of fecal microbiota transplantation in early life remains unclear. We established murine models using two age groups (3-week-old and 8-week-old mice) and two inoculation doses (low, 100 μL; high, 400 μL), with age-matched saline controls. High-dose fecal microbial administration in 3-week-old mice was associated with reduced weight gain, mild hypothermia, diarrhea, and multi-organ pathological changes, together with altered gut tight junction gene expression, elevated serum IL-6 and IL-1β, and increased Proteobacteria-associated bacterial DNA signals detected in extraintestinal tissues. In contrast, these effects were not observed in 8-week-old mice under the same conditions. Our findings suggest that early life may represent a susceptible window for adverse effects to high-dose fecal microbial exposure and support the need for age- and dose-stratified safety evaluation before pediatric application.
Indexed as
Identifiers
42622924What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.